The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Identifieur interne : 000C50 ( Main/Exploration ); précédent : 000C49; suivant : 000C51The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Auteurs : Anthony H. V. Schapira [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
English descriptors
- KwdEn :
Abstract
Levodopa is the ‘gold standard’ drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22146
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22146</idno><idno type="url">https://api.istex.fr/document/1E041800F6524CC2074E7F38AFFF9C8CE6212405/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001D57</idno><idno type="wicri:Area/Main/Curation">001A77</idno><idno type="wicri:Area/Main/Exploration">000C50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S515">S515</biblScope><biblScope unit="page" to="S520">S520</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E041800F6524CC2074E7F38AFFF9C8CE6212405</idno><idno type="DOI">10.1002/mds.22146</idno><idno type="ArticleID">MDS22146</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesias</term><term>levodopa</term><term>neuroprotection</term><term>toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the ‘gold standard’ drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1E041800F6524CC2074E7F38AFFF9C8CE6212405
|texte= The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |